Next Generation Products

Theregen's technology asset acquisition strategy has provided a portfolio of patents and licenses that it believes will also enable development of follow-on products for several large cardiovascular and vascular markets. These next-generation therapies are intended to be minimally invasive and are intended to complement treatment of ischemic disease in the heart and periphery.